Lavoltidine

Source: Wikipedia, the free encyclopedia.
Lavoltidine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
JSmol)
  • OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3

Lavoltidine (

gastric carcinoid tumors in rodents.[3][4]

See also

  • H2 receptor antagonist
  • hydroxyl
    group)

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). WHO Drug Information. 4 (3). World Health Organization: 7. 1990. Retrieved 12 January 2016.
  2. ^ "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
  3. ISBN 0-8493-5444-7
    .
  4. ISBN 0-412-54090-8
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lavoltidine&oldid=1190538707"